<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922812456238</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922812456238</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Presentation of Children With Premature Adrenarche</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>von Oettingen</surname><given-names>Julia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812456238">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sola Pou</surname><given-names>Joaquim</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0009922812456238">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Levitsky</surname><given-names>Lynne L.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922812456238">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Misra</surname><given-names>Madhusmita</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0009922812456238">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922812456238"><label>1</label>Massachusetts General Hospital for Children and Harvard Medical School, Boston, MA, USA</aff>
<aff id="aff2-0009922812456238"><label>2</label>Hospital Universitari de Girona, Girona, Spain</aff>
<author-notes>
<corresp id="corresp1-0009922812456238">Julia von Oettingen, Division of Pediatric Endocrinology, Massachusetts General Hospital for Children, 175 Cambridge Street, 5th Floor, Boston, MA 02114, USA Email: <email>julia.v.oettingen@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>51</volume>
<issue>12</issue>
<fpage>1140</fpage>
<lpage>1149</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Objectives</italic>. To describe the phenotype of premature adrenarche (PA) patients, elucidate historical and physical correlates, and distinguish PA from late-onset congenital adrenal hyperplasia (LOCAH). <italic>Study design</italic>. Retrospective chart review of 122 patients (91 female and 31 male) with PA and 11 with LOCAH. <italic>Results</italic>. In PA patients, birth weight was &lt;2 standard deviation scores (SDSs) in 6%, and 14% were premature. Body mass index SDSs were high (2.00 ± 1.84). Bone age (BA) SDS was &gt;2 in 31% and was greater in boys than in girls; PA subjects were taller, and the predicted height was at or above genetic potential. Dehydroepiandrosterone sulfate (DHEAS) was higher in boys. LOCAH patients had earlier pubic hair, more advanced BA, lower height SDSs, lower adult height prediction, and higher adrenal androgen levels. <italic>Conclusion</italic>. Patients with PA tend to be overweight with BA acceleration but normal height prediction. LOCAH is distinguished by earlier presentation and higher 17-hydrocyprogesterone and adrenal androgens.</p>
</abstract>
<kwd-group>
<kwd>congenital adrenal hyperplasia</kwd>
<kwd>17-hydroxyprogesterone</kwd>
<kwd>dehydroepiandrosterone sulfate</kwd>
<kwd>small for gestational age</kwd>
<kwd>low birth weight</kwd>
<kwd>bone age</kwd>
<kwd>advanced</kwd>
<kwd>precocious puberty</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0009922812456238" sec-type="intro">
<title>Introduction</title>
<p>Adrenarche is a physiological process defined by increased adrenal androgen production shortly before onset of gonadarche (the earliest detectable changes of puberty) and is associated with the appearance of apocrine body odor and acne or oily skin as well as pubic and axillary hair growth.<sup><xref ref-type="bibr" rid="bibr1-0009922812456238">1</xref>,<xref ref-type="bibr" rid="bibr2-0009922812456238">2</xref></sup> Premature adrenarche (PA) refers to the onset of such symptoms before the age of 8 years in girls and 9 years in boys and is usually associated with increasing levels of adrenal androgens into the pubertal range.<sup><xref ref-type="bibr" rid="bibr2-0009922812456238">2</xref></sup> Premature pubarche more specifically refers to the early onset of pubic and/or axillary hair growth in those age groups. Increased body mass index (BMI) has been associated with PA<sup><xref ref-type="bibr" rid="bibr2-0009922812456238">2</xref></sup> and with premature pubarche,<sup><xref ref-type="bibr" rid="bibr3-0009922812456238">3</xref></sup> and in some populations, low birth weight (BW) and smallness for gestational age (SGA) are reported to be risk factors.<sup><xref ref-type="bibr" rid="bibr4-0009922812456238">4</xref><xref ref-type="bibr" rid="bibr5-0009922812456238"/><xref ref-type="bibr" rid="bibr6-0009922812456238"/><xref ref-type="bibr" rid="bibr7-0009922812456238"/>-<xref ref-type="bibr" rid="bibr8-0009922812456238">8</xref></sup> Formerly believed to be a benign variant of normal adrenarche, there are now numerous reports linking PA to functional hyperandrogenism, polycystic ovary syndrome, hyperinsulinism, and the metabolic syndrome.<sup><xref ref-type="bibr" rid="bibr2-0009922812456238">2</xref>,<xref ref-type="bibr" rid="bibr9-0009922812456238">9</xref><xref ref-type="bibr" rid="bibr10-0009922812456238"/>-<xref ref-type="bibr" rid="bibr11-0009922812456238">11</xref></sup> PA needs to be distinguished from pathological conditions that may present with similar symptoms and require treatment, including late onset congenital adrenal hyperplasia (LOCAH) and virilizing adrenal or gonadal tumors.</p>
<p>The incidence of PA varies across different populations, with reports ranging from 5% to more than 30% and a higher incidence in Black and non-Hispanic White children.<sup><xref ref-type="bibr" rid="bibr4-0009922812456238">4</xref>,<xref ref-type="bibr" rid="bibr12-0009922812456238">12</xref>,<xref ref-type="bibr" rid="bibr13-0009922812456238">13</xref></sup> PA has been reported to be up to 10 times more common in girls than boys,<sup><xref ref-type="bibr" rid="bibr14-0009922812456238">14</xref></sup> with studies in girls outnumbering those in boys. Only a few reports exist of the entire spectrum of its clinical presentation in a large cohort and in both genders.<sup><xref ref-type="bibr" rid="bibr8-0009922812456238">8</xref>,<xref ref-type="bibr" rid="bibr15-0009922812456238">15</xref></sup></p>
<p>Our primary objective was to describe phenotypic characteristics, including clinical findings and anthropometric data of a large population of girls and boys with PA. We hypothesized that higher BMI, lower BW, and SGA would be associated with younger age at onset of adrenarche. Our secondary objective was to compare children who presented with PA but were subsequently diagnosed with LOCAH with children who had PA alone. We hypothesized that children with LOCAH would have earlier age of onset of adrenarche and would be clinically distinct from those with PA alone.</p>
</sec>
<sec id="section2-0009922812456238" sec-type="methods">
<title>Patients and Methods</title>
<p>This study is a retrospective chart review approved by the Partners Health Care Institutional Review Board and is compliant with the Health Insurance Portability and Accountability Act (HIPPA) in all procedures, data collection, and analysis. Because the study was retrospective, informed consent was not obtained from patients and families.</p>
<p>The patient log kept by the pediatric endocrine service of a large urban referral center was reviewed by a single investigator for patient charts coded as <italic>premature adrenarche</italic> or <italic>premature pubarche</italic> between January 1, 2003, and December 31, 2009. PA was defined as the presence of pubic or axillary hair with or without acne or apocrine odor before the age of 8 years in girls and before the age of 9 years in boys. Patients with early signs of adrenarche, including the symptoms per PA definition, were included in the study. Exclusion criteria were age greater than 8 years in girls and 9 years in boys at first symptom; any symptom of central puberty, including breast enlargement in girls and testicular volume greater than 3 cc in boys. For comparison of patients with PA with those who were eventually diagnosed with LOCAH, patient charts coded as <italic>CAH</italic> in the same time period were also reviewed. LOCAH was defined by elevation of 17-hydroxyprogesterone (17-OHP) to more than 200 ng/dL<sup><xref ref-type="bibr" rid="bibr16-0009922812456238">16</xref></sup> in addition to clinical symptoms out of the range for PA, and clinical follow-up was used to ascertain the diagnosis of LOCAH. Criteria for inclusion were the same as for PA patients. Exclusion criteria were detection of CAH on the newborn screen, diagnosis as a result of sibling diagnosis, or presenting symptom other than adrenarchal symptoms.</p>
<p>Of the 174 patients initially identified, we excluded 31 patients who had apocrine odor but no axillary or pubic hair and 10 patients who were younger than 12 months of age because the underlying pathophysiology of their condition could be distinct from that of older children with PA.<sup><xref ref-type="bibr" rid="bibr17-0009922812456238">17</xref></sup> The remaining 133 patients included 122 with PA per inclusion criteria and 11 who presented with symptoms of PA but were later diagnosed with LOCAH. The date of the initial visit and most likely diagnosis at presentation were recorded, as were parent-reported ethnicity, gender, birth date, BW, gestational age (GA), parental heights, age at the visit, and associated height, weight, and BMI. Parent reports of age at first appearance of pubic hair, axillary hair, acne, and apocrine body odor were recorded as were physical examination findings, including Tanner stage for pubic hair and breast development, presence or absence of axillary hair, body odor, acne, and acanthosis nigricans (indirect evidence of insulin resistance). Tanner staging was referenced as documented by the pediatric endocrinologist (n = 109) or by the pediatrician (n = 13) if the patient had initially been seen for symptoms of adrenarche without sexual hair but had documented axillary or pubic hair at a follow-up appointment before age 8 years in girls and 9 years in boys. Endocrine laboratory studies, including baseline levels of dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), 17-OHP, androstenedione, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone (FSH); adrenocorticotropic hormone (ACTH) stimulation test results; and age at laboratory testing were recorded. Given the large number of random blood draws, we did not limit our recording to 8 <sc>am</sc> samples. All bone age (BA) studies were documented, and we assessed readings by the endocrinologist and the radiologist. Midparental heights were calculated by dividing the sum of both parental heights by 2 and adding 6.5 cm for boys while subtracting 6.5 cm for girls.<sup><xref ref-type="bibr" rid="bibr18-0009922812456238">18</xref></sup> BW standard deviation scores (SDSs) were recorded using United States national reference data.<sup><xref ref-type="bibr" rid="bibr19-0009922812456238">19</xref></sup> National Center for Health Statistics 2000 data were referenced to calculate height and BMI SDSs.<sup><xref ref-type="bibr" rid="bibr20-0009922812456238">20</xref></sup> Standards of Greulich and Pyle were used to estimate BA SDSs and adult height prediction.</p>
<p>Statistical analysis was performed using JMP 2008. All results are presented as mean ± SD. Student’s <italic>t</italic> test was used for all paired and unpaired 1-sample and 2-sample tests. We determined associations between parameters of interest using Pearson’s correlation and performed a multivariate analysis to control for possible confounders among these associations. For all tests, an α level of .05 was used to indicate significance.</p>
</sec>
<sec id="section3-0009922812456238" sec-type="results">
<title>Results</title>
<sec id="section4-0009922812456238">
<title>Clinical Presentation and Demographics of Patients With PA</title>
<p>Of the 122 patients with PA, most were white, followed by Hispanic, black, Asian, and other or mixed ethnicity (<xref ref-type="table" rid="table1-0009922812456238">Table 1</xref>). The majority were girls, with a female to male ratio of 3:1 (91 female and 31 male patients). At presentation, 81 (66%) patients had pubic hair, 19 (16%) had axillary hair, and 22 (18%) had both axillary and pubic hair. In addition to these symptoms, 83 (68%) patients reported presence of body odor, and 19 (16%) had developed acne before the age of 8 years in girls and 9 years in boys. Eleven patients (9%) had acanthosis nigricans. Age at onset of first symptom was earlier in girls than boys for most but not all symptoms.</p>
<table-wrap id="table1-0009922812456238" position="float">
<label>Table 1.</label>
<caption>
<p>Demographics of the Study Population (PA Alone)<sup><xref ref-type="table-fn" rid="table-fn2-0009922812456238">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0009922812456238" xlink:href="10.1177_0009922812456238-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">n (%)</th>
<th align="center">Male Patients (%)</th>
<th align="center">Female Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Ethnicity</td>
</tr>
<tr>
<td> White</td>
<td>69 (57)</td>
<td>17 (55)</td>
<td>52 (57)</td>
</tr>
<tr>
<td> Hispanic</td>
<td>21 (17)</td>
<td>6 (19)</td>
<td>15 (16)</td>
</tr>
<tr>
<td> Black</td>
<td>13 (11)</td>
<td>4 (13)</td>
<td>9 (10)</td>
</tr>
<tr>
<td> Asian</td>
<td>5 (4)</td>
<td>1 (3)</td>
<td>4 (4)</td>
</tr>
<tr>
<td> Other/Mixed</td>
<td>14 (11)</td>
<td>3 (10)</td>
<td>11 (12)</td>
</tr>
<tr>
<td colspan="4">Ethnicity groups</td>
</tr>
<tr>
<td> Whites/Asians</td>
<td>74 (61)</td>
<td>18 (58)</td>
<td>56 (62)</td>
</tr>
<tr>
<td> Blacks/Hispanics</td>
<td>34 (28)</td>
<td>10 (32)</td>
<td>24 (26)</td>
</tr>
<tr>
<td colspan="4">Birth weight</td>
</tr>
<tr>
<td> &lt;−2 SDSs</td>
<td>7 (6)</td>
<td>1 (4)</td>
<td>6 (7)</td>
</tr>
<tr>
<td> &gt;−2 SDSs</td>
<td>105 (94)</td>
<td>26 (96)</td>
<td>79 (93)</td>
</tr>
<tr>
<td colspan="4">Gestational age</td>
</tr>
<tr>
<td> Full term (&gt;36 weeks)</td>
<td>98 (86)</td>
<td>24 (83)</td>
<td>74 (87)</td>
</tr>
<tr>
<td> Preterm (≤36 weeks)</td>
<td>16 (14)</td>
<td>5 (17)</td>
<td>11 (13)</td>
</tr>
<tr>
<td colspan="4">BMI SDS</td>
</tr>
<tr>
<td> 0-1</td>
<td>45 (37)</td>
<td>11 (35)</td>
<td>34 (37)</td>
</tr>
<tr>
<td> 1-2</td>
<td>21 (17)</td>
<td>4 (13)</td>
<td>17 (19)</td>
</tr>
<tr>
<td> &gt;2</td>
<td>57 (46)</td>
<td>16 (52)</td>
<td>41 (44)</td>
</tr>
<tr>
<td colspan="4">Sexual hair</td>
</tr>
<tr>
<td> Axillary hair</td>
<td>19 (16)</td>
<td>4 (13)</td>
<td>15 (16)</td>
</tr>
<tr>
<td> Pubic hair</td>
<td>81 (66)</td>
<td>24 (77)</td>
<td>57 (63)</td>
</tr>
<tr>
<td> Axillary + Pubic hair</td>
<td>22 (18)</td>
<td>3 (10)</td>
<td>19 (21)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0009922812456238">
<p>Abbreviations: PA, premature adrenarche; SDS, standard deviation score; BMI, body mass index.</p>
</fn>
<fn id="table-fn2-0009922812456238">
<label>a</label>
<p>There were no significant differences between male and female patients (all <italic>P</italic> values &gt;.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Hispanic and Black children generally had earlier onset of symptoms than White and Asian children (5.13 ± 1.82 vs 6.17 ± 1.55 years, <italic>P</italic> &lt; .003). They developed body odor earlier than their White and Asian peers (3.83 ± 1.82 vs 6.05 ± 1.49 years, <italic>P</italic> &lt; .001) and also had earlier onset of pubic hair (5.30 ± 1.51 vs 6.24 ± 1.29 years, <italic>P</italic> = .009). Boys in these ethnic groups only showed a trend toward earlier development of pubic hair (data not shown). BMI SDS trended highest in Hispanic children (2.65 ± 0.38), but this did not reach statistical significance.</p>
</sec>
<sec id="section5-0009922812456238">
<title>Birth Weights</title>
<p>Information regarding BW (<xref ref-type="table" rid="table1-0009922812456238">Tables 1</xref> and <xref ref-type="table" rid="table2-0009922812456238">2</xref>) was available for 112 patients and GA for 114 patients: 7 (6%) children had BWs below 2 SDSs for GA, and 16 (14%) children were born prematurely at &lt;37 weeks’ gestation.</p>
<table-wrap id="table2-0009922812456238" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison of Clinical and Biochemical Characteristics of Children Presenting With PA Across Genders</p>
</caption>
<graphic alternate-form-of="table2-0009922812456238" xlink:href="10.1177_0009922812456238-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Female Patients</th>
<th align="center">n (F)</th>
<th align="center">Male Patients</th>
<th align="center">n (M)</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Mean age at onset of symptoms (years)</td>
</tr>
<tr>
<td> Any symptom</td>
<td>5.54 ± 1.70</td>
<td>91</td>
<td>6.83 ± 1.69</td>
<td>31</td>
<td>.0002</td>
</tr>
<tr>
<td> Pubic hair, reported</td>
<td>6.06 ± 1.40</td>
<td>82</td>
<td>7.29 ± 1.12</td>
<td>30</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Pubic hair, physical exam</td>
<td>6.62 ± 1.18</td>
<td>82</td>
<td>7.93 ± 0.85</td>
<td>30</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Axillary hair, reported</td>
<td>6.28 ± 1.12</td>
<td>39</td>
<td>7.22 ± 1.14</td>
<td>10</td>
<td>.02</td>
</tr>
<tr>
<td> Axillary hair, physical exam</td>
<td>6.75 ± 1.03</td>
<td>47</td>
<td>7.69 ± 0.94</td>
<td>12</td>
<td>.006</td>
</tr>
<tr>
<td> Pubic or axillary hair, reported</td>
<td>6.01 ± 1.38</td>
<td>91</td>
<td>7.21 ± 1.12</td>
<td>31</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Pubic or axillary hair, physical exam</td>
<td>6.56 ± 1.21</td>
<td>91</td>
<td>7.90 ± 0.85</td>
<td>31</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Body odor, reported</td>
<td>5.55 ± 1.77</td>
<td>59</td>
<td>6.93 ± 1.15</td>
<td>24</td>
<td>.0007</td>
</tr>
<tr>
<td> Acne, reported</td>
<td>6.45 ± 1.15</td>
<td>12</td>
<td>6.85 ± 1.38</td>
<td>7</td>
<td>NS</td>
</tr>
<tr>
<td> Acanthosis nigricans</td>
<td>7.05 ± 1.29</td>
<td>8</td>
<td>8.17 ± 0.44</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td>Age at first visit (years)</td>
<td>6.60 ± 1.24</td>
<td>91</td>
<td>7.93 ± 0.85</td>
<td>31</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age at laboratory studies (years)</td>
<td>6.50 ± 1.33</td>
<td>57</td>
<td>7.88 ± 0.98</td>
<td>23</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age at BA assessment (years)</td>
<td>6.54 ± 1.24</td>
<td>90</td>
<td>7.88 ± 0.88</td>
<td>30</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td colspan="6">Birth data</td>
</tr>
<tr>
<td> BW (g)</td>
<td>3236 ± 889</td>
<td>85</td>
<td>3319 ± 772</td>
<td>27</td>
<td>NS</td>
</tr>
<tr>
<td> BW SDS</td>
<td>−0.09 ± 1.26</td>
<td>85</td>
<td>−0.21 ± 1.17</td>
<td>27</td>
<td>NS</td>
</tr>
<tr>
<td> Gestational age (weeks)</td>
<td>38.8 ± 3.3</td>
<td>85</td>
<td>39.0 ± 2.3</td>
<td>29</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6">Weight and BMI</td>
</tr>
<tr>
<td> Weight (kg)</td>
<td>30.1 ± 8.1</td>
<td>91</td>
<td>37.1 ± 9.5</td>
<td>31</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> BMI (kg/m<sup>2</sup>)</td>
<td>19.3 ± 3.4</td>
<td>91</td>
<td>20.5 ± 4.0</td>
<td>31</td>
<td>NS</td>
</tr>
<tr>
<td> BMI SDS</td>
<td>1.94 ± 1.82</td>
<td>91</td>
<td>2.17 ± 1.91</td>
<td>31</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6">BA data</td>
</tr>
<tr>
<td> BA SDS</td>
<td>1.25 ± 1.14</td>
<td>90</td>
<td>1.76 ± 1.32</td>
<td>30</td>
<td>.047</td>
</tr>
<tr>
<td> BA advancement (years)</td>
<td>0.97 ± 0.90</td>
<td>90</td>
<td>1.57 ± 1.16</td>
<td>30</td>
<td>.004</td>
</tr>
<tr>
<td colspan="6">Height and height prediction</td>
</tr>
<tr>
<td> Height SDS</td>
<td>0.99 ± 1.09</td>
<td>90</td>
<td>1.25 ± 1.24</td>
<td>31</td>
<td>NS</td>
</tr>
<tr>
<td> Predicted adult height (cm)</td>
<td>164.8 ± 9.4</td>
<td>75</td>
<td>181.8 ± 10.5</td>
<td>29</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Predicted adult height SDS</td>
<td>0.23 ± 1.45</td>
<td>75</td>
<td>0.70 ± 1.47</td>
<td>29</td>
<td>NS</td>
</tr>
<tr>
<td> Delta-predicted adult height, midparental height (cm)</td>
<td>0.26 ± 8.67</td>
<td>73</td>
<td>5.3 ± 10.4</td>
<td>28</td>
<td>.02</td>
</tr>
<tr>
<td> Delta-predicted adult height, midparental height SDS</td>
<td>0.04 ± 1.34</td>
<td>73</td>
<td>0.75 ± 1.47</td>
<td>28</td>
<td>.02</td>
</tr>
<tr>
<td colspan="6">Laboratory studies</td>
</tr>
<tr>
<td> DHEA (ng/mL)</td>
<td>7.6 ± 9.8</td>
<td>26</td>
<td>22.1 ± 17.5</td>
<td>7</td>
<td>.007</td>
</tr>
<tr>
<td> DHEAS (µg/dL)</td>
<td>65.1 ± 35.9</td>
<td>60</td>
<td>110.3 ± 40.5</td>
<td>20</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> 17-OHP (ng/dL)</td>
<td>51.3 ± 76.7</td>
<td>54</td>
<td>56.2 ± 60.5</td>
<td>22</td>
<td>NS</td>
</tr>
<tr>
<td> Androstenedione (ng/dL)</td>
<td>42.1 ± 29.1</td>
<td>16</td>
<td>51.7 ± 30.5</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td> Testosterone (ng/dL)</td>
<td>18.0 ± 7.4</td>
<td>49</td>
<td>19.9 ± 9.0</td>
<td>23</td>
<td>NS</td>
</tr>
<tr>
<td> Estradiol level (pg/mL)</td>
<td>19.3 ± 4.5</td>
<td>34</td>
<td align="center">—</td>
<td align="center">—</td>
<td>N/A</td>
</tr>
<tr>
<td> LH (U/L)</td>
<td>0.2 ± 0.3</td>
<td>42</td>
<td>0.1 ± 0.0</td>
<td>22</td>
<td>NS</td>
</tr>
<tr>
<td> FSH (U/L)</td>
<td>1.3 ± 0.9</td>
<td>43</td>
<td>0.8 ± 0.5</td>
<td>22</td>
<td>.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0009922812456238">
<p>Abbreviations: PA, premature adrenarche; F, female; M, male; BA, bone age; BW, birth weight; SDS, standard deviation score; BMI, body mass index; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17-hydroxyprogesterone; LH, luteinizing hormone; FSH, follicle stimulating hormone; NS, not significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0009922812456238">
<title>Anthropometry</title>
<p>BMI and BMI SDSs were calculated for all 122 patients (<xref ref-type="table" rid="table2-0009922812456238">Table 2</xref>). The BMI SDS was high (2.00 ± 1.84) and did not differ by gender. In all, 57 (46%) patients—41 (44%) girls and 16 (52%) boys—had a BMI SDS ≥2. Height SDS at presentation was elevated in both genders and did not differ between girls and boys.</p>
</sec>
<sec id="section7-0009922812456238">
<title>Bone Age Maturation</title>
<p>BA data were available for 120 patients (90 girls and 30 boys; <xref ref-type="table" rid="table2-0009922812456238">Table 2</xref>). BA was more advanced in boys compared with girls, as evidenced by higher BA SDSs and years of BA advancement (BA-chronological age). There were 22 (24%) girls and 14 (47%) boys with BA SDSs &gt;2. Predicted adult height SDS was calculated for 104 patients. In girls, the predicted adult height SDS did not differ from midparental height SDS (<italic>P</italic> = .46). However, in boys, the predicted adult height SDS was greater than midparental height SDS (<italic>P</italic> = .005). There was no influence of ethnic background on BA SDSs or adult height prediction.</p>
</sec>
<sec id="section8-0009922812456238">
<title>Biochemical Data</title>
<p>DHEAS was measured in 80 children and was in the pubertal range (&gt;40 µg/dL) in 62 (77.5%) patients<sup><xref ref-type="bibr" rid="bibr9-0009922812456238">9</xref>,<xref ref-type="bibr" rid="bibr21-0009922812456238">21</xref></sup> (<xref ref-type="table" rid="table2-0009922812456238">Table 2</xref>). DHEA was obtained in 33 patients and was in the prepubertal range in 21 (64%). Both DHEAS and DHEA were higher in boys than girls, and this difference persisted after controlling for age at testing. 17-OHP was measured in 76 patients, and levels were below 200 ng/dL in all but 3 children who did not otherwise differ from their peers. The highest baseline level (460 ng/dL) was found in a girl suspected to have mild deficiency of 21-hydroxylase or a heterozygote state (not confirmed with genetic testing). Levels of 17-OHP, androstenedione, and testosterone did not differ by gender. Luteinizing hormone and FSH were in the prepubertal range for all 65 patients who had these levels measured. Ethnicity did not influence biochemical parameters.</p>
<p>ACTH stimulation testing was performed in 15 patients (8 girls and 7 boys) at a mean age of 6.49 ± 2.23 years in girls and 8.24 ± 0.46 years in boys (<italic>P</italic> &lt; .06). Stimulation testing revealed normal results in all patients except for the above-mentioned girl suspected to have a mild deficiency of CYP21or heterozygosity for a CYP21 gene defect, whose poststimulation 17-OHP level was 812 ng/dL.</p>
</sec>
<sec id="section9-0009922812456238">
<title>Associations of BMI and BW With Age at Presentation, Maturity, and Biochemical Parameters</title>
<p>There was no association between BMI or BMI SDS and age at presentation. In girls but not in boys, higher BMI and BMI SDS correlated with more advanced BA (<xref ref-type="table" rid="table3-0009922812456238">Table 3</xref>), and BMI SDS &gt;2 was associated with a greater height SDS at presentation (<italic>P</italic> &lt; .02) and greater predicted height (<italic>P</italic> &lt; .04). A weak positive correlation was observed in all children between BMI SDS and testosterone levels (<italic>r</italic> = 0.25; <italic>P</italic> = .04) but no other hormone.</p>
<table-wrap id="table3-0009922812456238" position="float">
<label>Table 3.</label>
<caption>
<p>Associations Between BW, Weight, BMI, DHEAS, and BA Advancement (years)<sup><xref ref-type="table-fn" rid="table-fn5-0009922812456238">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table3-0009922812456238" xlink:href="10.1177_0009922812456238-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">Bone Age Advancement (SDS)<hr/></th>
<th align="center" colspan="4">Bone Age Advancement (years)<hr/></th>
</tr>
<tr>
<th/>
<th align="center" colspan="2">All Patients<hr/></th>
<th align="center" colspan="2">Girls<hr/></th>
<th align="center" colspan="2">All Patients<hr/></th>
<th align="center" colspan="2">Girls<hr/></th>
</tr>
<tr>
<th/>
<th align="center"><italic>r</italic></th>
<th align="center"><italic>P</italic></th>
<th align="center"><italic>r</italic></th>
<th align="center"><italic>P</italic></th>
<th align="center"><italic>r</italic></th>
<th align="center"><italic>P</italic></th>
<th align="center"><italic>r</italic></th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight</td>
<td>0.32</td>
<td>.0004</td>
<td>0.34</td>
<td>.0009</td>
<td>0.38</td>
<td>&lt;.0001</td>
<td>0.40</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>BMI</td>
<td>0.26</td>
<td>&lt;.005</td>
<td>0.35</td>
<td>.0007</td>
<td>0.28</td>
<td>.003</td>
<td>0.38</td>
<td>.0002</td>
</tr>
<tr>
<td>BMI SDS</td>
<td>0.24</td>
<td>&lt;.008</td>
<td>0.36</td>
<td>.0005</td>
<td>0.25</td>
<td>&lt;.007</td>
<td>0.37</td>
<td>.0003</td>
</tr>
<tr>
<td>DHEAS</td>
<td>0.31</td>
<td>&lt;.005</td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.37</td>
<td>.0008</td>
<td>0.27</td>
<td>.04</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0009922812456238">
<p>Abbreviations: BW, birth weight; BMI, body mass index; DHEAS, dehydroepiandrosterone sulfate; SDS, standard deviation score.</p>
</fn>
<fn id="table-fn5-0009922812456238">
<label>a</label>
<p>Only significant associations are reported. There were no significant associations with these parameters among boys.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>BW SDS did not predict age at onset of symptoms, nor was there an impact on BA advancement (data not shown). BW SDS predicted only lower height SDS in girls (<italic>r</italic> = 0.30; <italic>P</italic> = .006) and only lower weight in boys (<italic>r</italic> = 0.43; <italic>P</italic> = .03). BW and BW SDS correlated inversely with DHEAS (but not other hormones) at presentation in all patients (<italic>r</italic> = −0.36, <italic>P</italic> = .004, and <italic>r</italic> = −0.32, <italic>P</italic> = .007).</p>
</sec>
<sec id="section10-0009922812456238">
<title>Associations of Biochemical Parameters With Maturity</title>
<p>Higher DHEAS levels predicted higher BA advancement in the group as a whole (<xref ref-type="table" rid="table3-0009922812456238">Table 3</xref>), and this remained significant when adjusting for BMI, BMI SDS, weight, and age at presentation (data not shown). There was no discernable impact of any other hormone level on BA advancement.</p>
</sec>
<sec id="section11-0009922812456238">
<title>Comparison of PA and LOCAH Patients</title>
<p>The 11 patients diagnosed with LOCAH included 9 girls and 2 boys. All had pubic hair at presentation; 2 (18%) patients had both pubic and axillary hair. Four (36%) patients additionally had body odor at presentation, and 3 (27%) patients had acne. Children with LOCAH developed pubic hair at a younger age than children with PA but did not differ for age at onset of any other symptom (<xref ref-type="table" rid="table4-0009922812456238">Table 4</xref>). There was no difference in their birth data, including BW, BW SDS, and GA (data not shown). BMI SDS was lower in patients with LOCAH than PA. Their BAs were more advanced and predicted an adult height SDS that was lower than midparental height SDS compared with patients with PA, whose genetic potential was otherwise similar. Hormone levels were measured in all LOCAH patients. Levels of 17-OHP, DHEA, DHEAS, and androstenedione were higher compared with PA patients. Significance was lost for DHEAS but not other hormone levels when only girls were compared. There were no differences in testosterone and estradiol levels when comparing LOCAH versus PA.</p>
<table-wrap id="table4-0009922812456238" position="float">
<label>Table 4.</label>
<caption>
<p>Comparison of Clinical Presentation in Children With PA Versus LOCAH</p>
</caption>
<graphic alternate-form-of="table4-0009922812456238" xlink:href="10.1177_0009922812456238-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">PA</th>
<th align="center">n</th>
<th align="center">LOCAH</th>
<th align="center">n</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Mean age at onset of symptom (years)</td>
</tr>
<tr>
<td colspan="6"> Any symptom</td>
</tr>
<tr>
<td>  All patients</td>
<td>5.87 ± 1.67</td>
<td>122</td>
<td>5.15 ± 1.77</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>5.54 ± 1.70</td>
<td>91</td>
<td>4.83 ± 1.63</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Pubic hair, reported</td>
</tr>
<tr>
<td>  All patients</td>
<td>6.39 ± 1.43</td>
<td>112</td>
<td>5.41 ± 1.65</td>
<td>11</td>
<td>.0347</td>
</tr>
<tr>
<td>  Females</td>
<td>6.06 ± 1.40</td>
<td>82</td>
<td>4.87 ± 1.26</td>
<td>9</td>
<td>.0165</td>
</tr>
<tr>
<td colspan="6"> Axillary hair, reported</td>
</tr>
<tr>
<td>  All patients</td>
<td>6.47 ± 1.18</td>
<td>49</td>
<td>6.90 ± 0.97</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>6.34 ± 1.17</td>
<td>40</td>
<td>6.59 ± 0.76</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Pubic or axillary hair</td>
</tr>
<tr>
<td>  All patients</td>
<td>6.32 ± 1.42</td>
<td>122</td>
<td>5.55 ± 1.63</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>6.01 ± 1.38</td>
<td>91</td>
<td>5.04 ± 1.30</td>
<td>9</td>
<td>.0452</td>
</tr>
<tr>
<td colspan="6"> Body odor</td>
</tr>
<tr>
<td>  All patients</td>
<td>5.95 ± 1.72</td>
<td>83</td>
<td>4.92 ± 2.53</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>5.55 ± 1.77</td>
<td>59</td>
<td>3.83 ± 1.61</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Acne</td>
</tr>
<tr>
<td>  All patients</td>
<td>6.60 ± 1.22</td>
<td>19</td>
<td>7.06 ± 1.78</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>6.45 ± 1.15</td>
<td>12</td>
<td>8.0</td>
<td>1</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Age at first visit (years)</td>
</tr>
<tr>
<td>  All patients</td>
<td>6.93 ± 1.29</td>
<td>122</td>
<td>7.53 ± 1.83</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>6.60 ± 1.24</td>
<td>91</td>
<td>7.24 ± 1.91</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6">Weight, BMI, bone age</td>
</tr>
<tr>
<td colspan="6"> Weight (kg)</td>
</tr>
<tr>
<td>  All patients</td>
<td>31.9 ± 9.0</td>
<td>122</td>
<td>29.9 ± 8.7</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>30.1 ± 8.1</td>
<td>91</td>
<td>27.7 ± 7.3</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> BMI (kg/m<sup>2</sup>)</td>
</tr>
<tr>
<td>  All patients</td>
<td>19.6 ± 3.57</td>
<td>122</td>
<td>17.5 ± 2.58</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>19.3 ± 3.39</td>
<td>91</td>
<td>17.1 ± 2.25</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> BMI SDS</td>
</tr>
<tr>
<td>  All patients</td>
<td>2.00 ± 1.84</td>
<td>122</td>
<td>0.58 ± 1.07</td>
<td>11</td>
<td>.0130</td>
</tr>
<tr>
<td>  Females</td>
<td>1.94 ± 1.82</td>
<td>91</td>
<td>0.44 ± 0.89</td>
<td>9</td>
<td>.0163</td>
</tr>
<tr>
<td colspan="6"> BA SDS</td>
</tr>
<tr>
<td>  All patients</td>
<td>1.38 ± 1.20</td>
<td>120</td>
<td>2.41 ± 1.53</td>
<td>11</td>
<td>.0089</td>
</tr>
<tr>
<td>  Females</td>
<td>1.25 ± 1.14</td>
<td>90</td>
<td>2.07 ± 1.48</td>
<td>9</td>
<td>.0497</td>
</tr>
<tr>
<td colspan="6"> BA advancement (years)</td>
</tr>
<tr>
<td>  All patients</td>
<td>1.12 ± 1.00</td>
<td>120</td>
<td>2.20 ± 1.39</td>
<td>11</td>
<td>.0013</td>
</tr>
<tr>
<td>  Females</td>
<td>0.97 ± 0.90</td>
<td>90</td>
<td>1.90 ± 1.36</td>
<td>9</td>
<td>.0063</td>
</tr>
<tr>
<td colspan="6">Height and height prediction</td>
</tr>
<tr>
<td colspan="6"> Height SDS</td>
</tr>
<tr>
<td>  All patients</td>
<td>1.06 ± 1.13</td>
<td>121</td>
<td>0.93 ± 1.08</td>
<td>11</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>0.99 ± 1.09</td>
<td>90</td>
<td>0.77 ± 1.09</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Midparental height (cm)</td>
</tr>
<tr>
<td>  All patients</td>
<td>168.0 ± 8.25</td>
<td>118</td>
<td>166.6 ± 7.71</td>
<td>10</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>164.9 ± 6.0</td>
<td>88</td>
<td>163.1 ± 2.23</td>
<td>8</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Midparental height SDS</td>
</tr>
<tr>
<td>  All patients</td>
<td>0.19 ± 0.96</td>
<td>117</td>
<td>0.07 ± 0.45</td>
<td>10</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>0.24 ± 0.93</td>
<td>88</td>
<td>−0.03 ± 0.34</td>
<td>8</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Predicted height (cm)</td>
</tr>
<tr>
<td>  All patients</td>
<td>169.5 ± 12.3</td>
<td>104</td>
<td>158.5 ± 9.5</td>
<td>10</td>
<td>.0070</td>
</tr>
<tr>
<td>  Females</td>
<td>164.8 ± 9.4</td>
<td>75</td>
<td>155.0 ± 5.8</td>
<td>8</td>
<td>.0049</td>
</tr>
<tr>
<td colspan="6">(continued)</td>
</tr>
<tr>
<td colspan="6"> Predicted height SDS</td>
</tr>
<tr>
<td>  All patients</td>
<td>0.36 ± 1.47</td>
<td>104</td>
<td>−1.14 ± 0.93</td>
<td>10</td>
<td>.0019</td>
</tr>
<tr>
<td>  Females</td>
<td>0.23 ± 1.45</td>
<td>75</td>
<td>−1.28 ± 0.90</td>
<td>8</td>
<td>.0051</td>
</tr>
<tr>
<td colspan="6"> Delta predicted - midparental height (cm)</td>
</tr>
<tr>
<td>  All patients</td>
<td>1.7 ± 9.4</td>
<td>101</td>
<td>−8.0 ± 5.1</td>
<td>10</td>
<td>.0018</td>
</tr>
<tr>
<td>  Females</td>
<td>0.3 ± 8.7</td>
<td>73</td>
<td>−8.14 ± 5.6</td>
<td>8</td>
<td>.0092</td>
</tr>
<tr>
<td colspan="6"> Delta predicted - midparental height SDS</td>
</tr>
<tr>
<td>  All patients</td>
<td>0.23 ± 1.41</td>
<td>100</td>
<td>−1.21 ± 0.78</td>
<td>10</td>
<td>.0019</td>
</tr>
<tr>
<td>  Females</td>
<td>0.04 ± 1.34</td>
<td>73</td>
<td>−1.25 ± 0.86</td>
<td>8</td>
<td>.0095</td>
</tr>
<tr>
<td colspan="6">Laboratory studies</td>
</tr>
<tr>
<td colspan="6"> DHEA (ng/mL)</td>
</tr>
<tr>
<td>  All patients</td>
<td>10.6 ± 13.0</td>
<td>33</td>
<td>32.5 ± 30.0</td>
<td>6</td>
<td>.0048</td>
</tr>
<tr>
<td>  Females</td>
<td>7.57 ± 9.8</td>
<td>26</td>
<td>32.5 ± 30.0</td>
<td>6</td>
<td>.0011</td>
</tr>
<tr>
<td colspan="6"> DHEAS (µg/dL)</td>
</tr>
<tr>
<td>  All patients</td>
<td>76.4 ± 41.7</td>
<td>80</td>
<td>156.6 ± 134.2</td>
<td>5</td>
<td>.0009</td>
</tr>
<tr>
<td>  Females</td>
<td>65.1 ± 35.9</td>
<td>60</td>
<td>102.3 ± 65.8</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> 17-OHP (ng/dL)</td>
</tr>
<tr>
<td>  All patients</td>
<td>52.7 ± 72.0</td>
<td>76</td>
<td>1125 ± 866</td>
<td>10</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>  Females</td>
<td>51.3 ± 42.2</td>
<td>54</td>
<td>1009.1 ± 832.7</td>
<td>9</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td colspan="6"> Androstenedione (ng/dL)</td>
</tr>
<tr>
<td>  All patients</td>
<td>45.5 ± 29.4</td>
<td>25</td>
<td>104 ± 77.2</td>
<td>8</td>
<td>.0031</td>
</tr>
<tr>
<td>  Females</td>
<td>42.1 ± 29.1</td>
<td>16</td>
<td>103.3 ± 83.3</td>
<td>7</td>
<td>.0148</td>
</tr>
<tr>
<td colspan="6"> Testosterone (ng/dL)</td>
</tr>
<tr>
<td>  All patients</td>
<td>18.6 ± 7.9</td>
<td>22.9</td>
<td>20.1 ± 6.3</td>
<td>10</td>
<td>NS</td>
</tr>
<tr>
<td>  Females</td>
<td>18.0 ± 7.4</td>
<td>49</td>
<td>17.2 ± 9.5</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"> Estradiol (pg/mL)</td>
</tr>
<tr>
<td>  Females</td>
<td>19.3 ± 4.5</td>
<td>34</td>
<td>20 ± 0</td>
<td>3</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0009922812456238">
<p>Abbreviations: PA, premature adrenarche; LOCAH, late onset congenital adrenal hyperplasia; BA, bone age; BW, birth weight; SDS, standard deviation score; BMI, body mass index; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17-hydroxyprogesterone; NS, not significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0009922812456238" sec-type="discussion">
<title>Discussion</title>
<p>We describe clinical, anthropometric, laboratory, and BA findings in one of the largest cohorts reported thus far of US children with PA. To our knowledge, this is the largest study to date that also includes a subset of boys with PA. We additionally report a comprehensive overview of the differences in presentation between children with PA and those diagnosed with LOCAH. Whereas most reports on PA are in girls,<sup><xref ref-type="bibr" rid="bibr22-0009922812456238">22</xref><xref ref-type="bibr" rid="bibr23-0009922812456238"/><xref ref-type="bibr" rid="bibr24-0009922812456238"/>-<xref ref-type="bibr" rid="bibr25-0009922812456238">25</xref></sup> some studies have included small numbers of boys.<sup><xref ref-type="bibr" rid="bibr6-0009922812456238">6</xref>,<xref ref-type="bibr" rid="bibr7-0009922812456238">7</xref>,<xref ref-type="bibr" rid="bibr26-0009922812456238">26</xref><xref ref-type="bibr" rid="bibr27-0009922812456238"/>-<xref ref-type="bibr" rid="bibr28-0009922812456238">28</xref></sup> To our knowledge, this is the first study specifically describing differences in presentation between genders. Girls were symptomatic about 14 to 17 months earlier than boys, consistent with previous descriptions of earlier pubarche<sup><xref ref-type="bibr" rid="bibr3-0009922812456238">3</xref>,<xref ref-type="bibr" rid="bibr13-0009922812456238">13</xref></sup> and lower age cutoff for PA in girls. The majority (63%) of both boys and girls in our study were either overweight or obese, a phenomenon frequently recognized in girls with PA<sup><xref ref-type="bibr" rid="bibr8-0009922812456238">8</xref>,<xref ref-type="bibr" rid="bibr29-0009922812456238">29</xref>,<xref ref-type="bibr" rid="bibr30-0009922812456238">30</xref></sup> and in at least 1 study that included both genders.<sup><xref ref-type="bibr" rid="bibr26-0009922812456238">26</xref></sup> As in previous reports,<sup><xref ref-type="bibr" rid="bibr1-0009922812456238">1</xref>,<xref ref-type="bibr" rid="bibr24-0009922812456238">24</xref>,<xref ref-type="bibr" rid="bibr31-0009922812456238">31</xref><xref ref-type="bibr" rid="bibr32-0009922812456238"/>-<xref ref-type="bibr" rid="bibr33-0009922812456238">33</xref></sup> height SDS and BA were advanced in both genders. A substantial number of patients—close to 1 in 4 girls and half the boys—had BA SDS ≥2 without associated pathology. In girls, this BA advancement did not affect adult height prediction, consistent with a most recent report that found normal adult heights despite BA advancement at presentation.<sup><xref ref-type="bibr" rid="bibr34-0009922812456238">34</xref></sup> The effect of BA advancement on adult height in boys has not been elucidated. Surprisingly, we found that the predicted adult height SDS in boys was greater than their midparental height SDS. We do not have adult height data for our cohort. It is possible that growth prediction using current standards is less accurate in boys with PA.</p>
<p>In our cohort, BMI, BMI SDS, and weight were independent predictors of BA advancement in girls but not boys, and higher DHEAS levels predicted greater BA advancement for the group as a whole. These findings raise the possibility that, as previously suggested,<sup><xref ref-type="bibr" rid="bibr35-0009922812456238">35</xref></sup> increased body fat and subsequent increases in aromatization of androgens to estrogen in adipose tissue are responsible for BA advancement in girls. However, in boys who have higher DHEAS levels than girls, the main driving force for BA advancement most likely is conversion of adrenal androgens to estrogen. Although we found no association between other adrenal androgens and BA advancement, it is possible that our cohort lacked sufficient power to detect such associations.</p>
<p>Low BW and prematurity have been reported to predispose to PA in some study populations<sup><xref ref-type="bibr" rid="bibr5-0009922812456238">5</xref>,<xref ref-type="bibr" rid="bibr6-0009922812456238">6</xref>,<xref ref-type="bibr" rid="bibr36-0009922812456238">36</xref></sup> but not others.<sup><xref ref-type="bibr" rid="bibr7-0009922812456238">7</xref>,<xref ref-type="bibr" rid="bibr8-0009922812456238">8</xref>,<xref ref-type="bibr" rid="bibr24-0009922812456238">24</xref>,<xref ref-type="bibr" rid="bibr37-0009922812456238">37</xref></sup> In our cohort, mean BW was close to the norm and did not differ between genders or ethnicities. The observed number of children with BW &lt;2 SDSs was higher than statistically expected, and similarly, the proportion of children born prematurely was higher than the expected 11% to 12%.<sup><xref ref-type="bibr" rid="bibr38-0009922812456238">38</xref></sup> However, both elevations were modest and do not with certainty confirm prematurity or SGA as risk factors for PA. We could not discern any clinical findings that distinguished SGA from normal BW children but confirmed the previously reported inverse association of BW with DHEAS. This may represent biochemical evidence of earlier adrenarche in children with lower BW.</p>
<p>In this study, we highlighted differences in clinical presentation between children with PA versus LOCAH. Clinical features are generally believed to have poor predictive power in distinguishing between the 2 conditions.<sup><xref ref-type="bibr" rid="bibr17-0009922812456238">17</xref></sup> In our cohort, age at onset of pubic hair and BMI SDSs were lower, BA was more advanced, and height SDSs as well as predicted adult heights were lower in patients with LOCAH when compared with those with PA. Traditionally, BA advancement ≥2 SDSs is considered suspicious for LOCAH or other pathology. Here, 63% of LOCAH patients had BA SDSs ≥2, although this was also true for 24% of girls and 47% of boys with PA. Given concurrent lower height SDS at presentation and lower predicted adult height compared with genetic target height in children with LOCAH, a combination of these factors, rather than greater advancement in BA alone, should prompt a higher suspicion of LOCAH. Laboratory studies are helpful in further distinguishing between the 2 conditions, and our data support the assertion that a baseline 17-OHP level can reliably detect children with LOCAH.<sup><xref ref-type="bibr" rid="bibr16-0009922812456238">16</xref></sup> A cutoff of 200 ng/dL yielded a sensitivity of 100% and a specificity of 96% in our patient population, with 3 patients who were diagnosed with PA having levels above the cutoff but clinical symptoms at presentation and at follow-up that were consistent with PA as opposed to LOCAH. For these specific patients, genetic testing would likely have been helpful to further ascertain their diagnosis.</p>
<p>The limitations of our study include its retrospective nature and resulting missed data for certain parameters. One third of our patients did not undergo laboratory testing during the recorded time period, raising concerns that our laboratory data are skewed toward children with a more concerning clinical picture at presentation. However, it seems likely that this relates more to differences in management by various physicians than differences in patient presentation. Conversely, rates for anthropometric data collection and BA studies approached 100%, and there was no discernible difference between children who had laboratory testing and those who did not (data not shown). Only a small percentage of children (12%) underwent ACTH testing, and we did not have molecular confirmation of LOCAH in some patients. This may have led to a classification bias and an underestimation of LOCAH in our population. However, the calculated prevalence of LOCAH of 8% within our cohort falls within the expected wider range of 0% (see Morris et al<sup><xref ref-type="bibr" rid="bibr39-0009922812456238">39</xref></sup>) to 40% (see Temeck et al<sup><xref ref-type="bibr" rid="bibr40-0009922812456238">40</xref></sup>) and above the generally expected narrower range of 3% to 6%.<sup><xref ref-type="bibr" rid="bibr33-0009922812456238">33</xref></sup> Our cohort was selected from a major urban referral center, and we cannot exclude the possibility of referral or selection bias. However, our data are consistent with published results using smaller data sets.</p>
</sec>
<sec id="section13-0009922812456238" sec-type="conclusions">
<title>Conclusion</title>
<p>We present detailed clinical, anthropometric, hormonal, and BA characteristics of a large population of girls and boys presenting with PA in comparison to a group with similar clinical symptoms but a subsequent diagnosis of LOCAH. We were able to confirm previously reported associations of PA with increased weight and BMI, increased height SDS, and advanced BA but normal height predictions. We were able to elucidate some suspected differences in ethnic background that relate to PA. Without being able to draw conclusions for clinical guidelines, these studies are cautionary in regard to the use of BA data rather than height prediction to determine the need for screening for LOCAH, and they provide reassurance that baseline 17-OHP testing is a sensitive screening test for LOCAH. Large prospective long-term studies of children with PA to confirm these findings and understand differences between boys and girls and children of varied ethnic backgrounds would be useful for clinical care.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<label>Authors’ Note</label>
<p>We do not have any prior publication or submission with any overlapping information to disclose. We do not have any conflict of interest to disclose. Dr von Oettingen wrote the first draft of the article. No honorarium, grant, or other form of payment was given to anyone to produce the article. Dr von Oettingen contributed to study design, data acquisition, analysis and interpretation, and the writing and revisions of the article. Dr Sola Pou worked on data acquisition and article revisions. Dr Levitsky contributed to study conception, study design, and data interpretation and also reviewed the article critically for intellectual content. Dr Misra contributed to study concept, design, data analysis, and interpretation and reviewed and revised the article for intellectual content. Each author listed on the article has seen and approved the submission of this version of the article and takes full responsibility for the article.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922812456238">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voutilainen</surname><given-names>R</given-names></name>
<name><surname>Perheentupa</surname><given-names>J</given-names></name>
<name><surname>Apter</surname><given-names>D</given-names></name>
</person-group>. <article-title>Benign premature adrenarche: clinical features and serum steroid levels</article-title>. <source>Acta Paediatr Scand</source>. <year>1983</year>;<volume>72</volume>:<fpage>707</fpage>-<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr2-0009922812456238">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Dimartino-Nardi</surname><given-names>J</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Premature adrenarche: normal variant or forerunner of adult disease?</article-title> <source>Endocr Rev</source>. <year>2000</year>;<volume>21</volume>:<fpage>671</fpage>-<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr3-0009922812456238">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfield</surname><given-names>RL</given-names></name>
<name><surname>Lipton</surname><given-names>RB</given-names></name>
<name><surname>Drum</surname><given-names>ML</given-names></name>
</person-group>. <article-title>Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index</article-title>. <source>Pediatrics</source>. <year>2009</year>;<volume>123</volume>:<fpage>84</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr4-0009922812456238">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<name><surname>Francois</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1998</year>;<volume>83</volume>:<fpage>3558</fpage>-<lpage>3562</lpage>.</citation>
</ref>
<ref id="bibr5-0009922812456238">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<name><surname>Marcos</surname><given-names>MV</given-names></name>
<etal/>
</person-group>. <article-title>Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1999</year>;<volume>84</volume>:<fpage>4739</fpage>-<lpage>4741</lpage>.</citation>
</ref>
<ref id="bibr6-0009922812456238">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neville</surname><given-names>KA</given-names></name>
<name><surname>Walker</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity</article-title>. <source>Arch Dis Child</source>. <year>2005</year>;<volume>90</volume>:<fpage>258</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr7-0009922812456238">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paterson</surname><given-names>WF</given-names></name>
<name><surname>Ahmed</surname><given-names>SF</given-names></name>
<name><surname>Bath</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Exaggerated adrenarche in a cohort of Scottish children: clinical features and biochemistry</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2010</year>;<volume>72</volume>:<fpage>496</fpage>-<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr8-0009922812456238">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Utriainen</surname><given-names>P</given-names></name>
<name><surname>Jaaskelainen</surname><given-names>J</given-names></name>
<name><surname>Romppanen</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Childhood metabolic syndrome and its components in premature adrenarche</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>:<fpage>4282</fpage>-<lpage>4285</lpage>.</citation>
</ref>
<ref id="bibr9-0009922812456238">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Diaz</surname><given-names>R</given-names></name>
<name><surname>Lopez-Bermejo</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism</article-title>. <source>Rev Endocr Metab Disord</source>. <year>2009</year>;<volume>10</volume>:<fpage>63</fpage>-<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr10-0009922812456238">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<name><surname>Chacon</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Hyperinsulinaemia, dyslipidaemia and cardiovascular risk in girls with a history of premature pubarche</article-title>. <source>Diabetologia</source>. <year>1998</year>;<volume>41</volume>:<fpage>1057</fpage>-<lpage>1063</lpage>.</citation>
</ref>
<ref id="bibr11-0009922812456238">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<name><surname>Virdis</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1993</year>;<volume>76</volume>:<fpage>1599</fpage>-<lpage>1603</lpage>.</citation>
</ref>
<ref id="bibr12-0009922812456238">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zukauskaite</surname><given-names>S</given-names></name>
<name><surname>Lasiene</surname><given-names>D</given-names></name>
<name><surname>Lasas</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Onset of breast and pubic hair development in 1231 preadolescent Lithuanian schoolgirls</article-title>. <source>Arch Dis Child</source>. <year>2005</year>;<volume>90</volume>:<fpage>932</fpage>-<lpage>936</lpage>.</citation>
</ref>
<ref id="bibr13-0009922812456238">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman-Giddens</surname><given-names>ME</given-names></name>
<name><surname>Slora</surname><given-names>EJ</given-names></name>
<name><surname>Wasserman</surname><given-names>RC</given-names></name>
<etal/>
</person-group>. <article-title>Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network</article-title>. <source>Pediatrics</source>. <year>1997</year>;<volume>99</volume>:<fpage>505</fpage>-<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr14-0009922812456238">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfield</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Normal and almost normal precocious variations in pubertal development premature pubarche and premature thelarche revisited</article-title>. <source>Horm Res</source>. <year>1994</year>;<volume>41</volume>(<supplement>suppl 2</supplement>):<fpage>7</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr15-0009922812456238">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balducci</surname><given-names>R</given-names></name>
<name><surname>Boscherini</surname><given-names>B</given-names></name>
<name><surname>Mangiantini</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Isolated precocious pubarche: an approach</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1994</year>;<volume>79</volume>:<fpage>582</fpage>-<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr16-0009922812456238">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Armengaud</surname><given-names>JB</given-names></name>
<name><surname>Charkaluk</surname><given-names>ML</given-names></name>
<name><surname>Trivin</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2009</year>;<volume>94</volume>:<fpage>2835</fpage>-<lpage>2840</lpage>.</citation>
</ref>
<ref id="bibr17-0009922812456238">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nebesio</surname><given-names>TD</given-names></name>
<name><surname>Eugster</surname><given-names>EA</given-names></name>
</person-group>. <article-title>Pubic hair of infancy: endocrinopathy or enigma?</article-title> <source>Pediatrics</source>. <year>2006</year>;<volume>117</volume>:<fpage>951</fpage>-<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr18-0009922812456238">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanner</surname><given-names>JM</given-names></name>
<name><surname>Goldstein</surname><given-names>H</given-names></name>
<name><surname>Whitehouse</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Standards for children’s height at ages 2-9 years allowing for heights of parents</article-title>. <source>Arch Dis Child</source>. <year>1970</year>;<volume>45</volume>:<fpage>755</fpage>-<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr19-0009922812456238">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oken</surname><given-names>E</given-names></name>
<name><surname>Kleinman</surname><given-names>KP</given-names></name>
<name><surname>Rich-Edwards</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A nearly continuous measure of birth weight for gestational age using a United States national reference</article-title>. <source>BMC Pediatr</source>. <year>2003</year>;<volume>3</volume>:<fpage>6</fpage>.</citation>
</ref>
<ref id="bibr20-0009922812456238">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuczmarski</surname><given-names>RJ</given-names></name>
<name><surname>Ogden</surname><given-names>CL</given-names></name>
<name><surname>Guo</surname><given-names>SS</given-names></name>
<etal/>
</person-group>. <article-title>2000 CDC Growth Charts for the United States: methods and development</article-title>. <source>Vital Health Stat 11</source>. <year>2002</year>;(<issue>246</issue>):<fpage>1</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr21-0009922812456238">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenfield</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Clinical review: identifying children at risk for polycystic ovary syndrome</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2007</year>;<volume>92</volume>:<fpage>787</fpage>-<lpage>796</lpage>.</citation>
</ref>
<ref id="bibr22-0009922812456238">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banerjee</surname><given-names>S</given-names></name>
<name><surname>Raghavan</surname><given-names>S</given-names></name>
<name><surname>Wasserman</surname><given-names>EJ</given-names></name>
<etal/>
</person-group>. <article-title>Hormonal findings in African-American and Caribbean Hispanic girls with premature adrenarche: implications for polycystic ovarian syndrome</article-title>. <source>Pediatrics</source>. <year>1998</year>;<volume>102</volume>:<fpage>E36</fpage>.</citation>
</ref>
<ref id="bibr23-0009922812456238">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Ferran</surname><given-names>K</given-names></name>
<name><surname>Paiva</surname><given-names>IA</given-names></name>
<name><surname>Garcia Ldos</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Isolated premature pubarche: report of anthropometric and metabolic profile of a Brazilian cohort of girls</article-title>. <source>Horm Res Paediatr</source>. <year>2011</year>;<volume>75</volume>:<fpage>367</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr24-0009922812456238">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghizzoni</surname><given-names>L</given-names></name>
<name><surname>Milani</surname><given-names>S</given-names></name>
</person-group>. <article-title>The natural history of premature adrenarche</article-title>. <source>J Pediatr Endocrinol Metab</source>. <year>2000</year>;<volume>13</volume>(<supplement>suppl 5</supplement>):<fpage>1247</fpage>-<lpage>1251</lpage>.</citation>
</ref>
<ref id="bibr25-0009922812456238">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Girgis</surname><given-names>R</given-names></name>
<name><surname>Abrams</surname><given-names>SA</given-names></name>
<name><surname>Castracane</surname><given-names>VD</given-names></name>
<etal/>
</person-group>. <article-title>Ethnic differences in androgens, IGF-I and body fat in healthy prepubertal girls</article-title>. <source>J Pediatr Endocrinol Metab</source>. <year>2000</year>;<volume>13</volume>:<fpage>497</fpage>-<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr26-0009922812456238">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diaz</surname><given-names>A</given-names></name>
<name><surname>Bhandari</surname><given-names>S</given-names></name>
<name><surname>Sison</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Characteristics of children with premature pubarche in the New York metropolitan area</article-title>. <source>Horm Res</source>. <year>2008</year>;<volume>70</volume>:<fpage>150</fpage>-<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr27-0009922812456238">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balducci</surname><given-names>R</given-names></name>
<name><surname>Boscherini</surname><given-names>B</given-names></name>
<name><surname>Mangiantini</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Isolated precocious pubarche: an approach</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1994</year>;<volume>79</volume>:<fpage>582</fpage>-<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr28-0009922812456238">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Likitmaskul</surname><given-names>S</given-names></name>
<name><surname>Cowell</surname><given-names>CT</given-names></name>
<name><surname>Donaghue</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Exaggerated adrenarche in children presenting with premature adrenarche</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>1995</year>;<volume>42</volume>:<fpage>265</fpage>-<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr29-0009922812456238">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Remer</surname><given-names>T</given-names></name>
<name><surname>Manz</surname><given-names>F</given-names></name>
</person-group>. <article-title>Role of nutritional status in the regulation of adrenarche</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1999</year>;<volume>84</volume>:<fpage>3936</fpage>-<lpage>3944</lpage>.</citation>
</ref>
<ref id="bibr30-0009922812456238">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ong</surname><given-names>KK</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<name><surname>Petry</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>:<fpage>2647</fpage>-<lpage>2651</lpage>.</citation>
</ref>
<ref id="bibr31-0009922812456238">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaplowitz</surname><given-names>PB</given-names></name>
<name><surname>Cockrell</surname><given-names>JL</given-names></name>
<name><surname>Young</surname><given-names>RB</given-names></name>
</person-group>. <article-title>Premature adrenarche: clinical and diagnostic features</article-title>. <source>Clin Pediatr (Phila)</source>. <year>1986</year>;<volume>25</volume>:<fpage>28</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr32-0009922812456238">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pere</surname><given-names>A</given-names></name>
<name><surname>Perheentupa</surname><given-names>J</given-names></name>
<name><surname>Peter</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Follow up of growth and steroids in premature adrenarche</article-title>. <source>Eur J Pediatr</source>. <year>1995</year>;<volume>154</volume>:<fpage>346</fpage>-<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr33-0009922812456238">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibanez</surname><given-names>L</given-names></name>
<name><surname>Virdis</surname><given-names>R</given-names></name>
<name><surname>Potau</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Natural history of premature pubarche: an auxological study</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1992</year>;<volume>74</volume>:<fpage>254</fpage>-<lpage>257</lpage>.</citation>
</ref>
<ref id="bibr34-0009922812456238">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oron</surname><given-names>T</given-names></name>
<name><surname>Lebenthal</surname><given-names>Y</given-names></name>
<name><surname>de Vries</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Interrelationship of extent of precocious adrenarche in appropriate for gestational age girls with clinical outcome</article-title>. <source>J Pediatr</source>. <year>2012</year>;<volume>160</volume>:<fpage>308</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr35-0009922812456238">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sopher</surname><given-names>AB</given-names></name>
<name><surname>Jean</surname><given-names>AM</given-names></name>
<name><surname>Zwany</surname><given-names>SK</given-names></name>
<etal/>
</person-group>. <article-title>Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors</article-title>. <source>Obesity</source>. <year>2011</year>;<volume>19</volume>:<fpage>1259</fpage>-<lpage>1264</lpage>.</citation>
</ref>
<ref id="bibr36-0009922812456238">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charkaluk</surname><given-names>ML</given-names></name>
<name><surname>Trivin</surname><given-names>C</given-names></name>
<name><surname>Brauner</surname><given-names>R</given-names></name>
</person-group>. <article-title>Premature pubarche as an indicator of how body weight influences the onset of adrenarche</article-title>. <source>Eur J Pediatr</source>. <year>2004</year>;<volume>163</volume>:<fpage>89</fpage>-<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr37-0009922812456238">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meas</surname><given-names>T</given-names></name>
<name><surname>Chevenne</surname><given-names>D</given-names></name>
<name><surname>Thibaud</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Endocrine consequences of premature pubarche in post-pubertal Caucasian girls</article-title>. <source>Clin Endocrinol (Oxf)</source>. <year>2002</year>;<volume>57</volume>:<fpage>101</fpage>-<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr38-0009922812456238">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>JA</given-names></name>
<name><surname>Osterman</surname><given-names>MJ</given-names></name>
<name><surname>Sutton</surname><given-names>PD</given-names></name>
</person-group>. <article-title>Are preterm births on the decline in the United States? Recent data from the National Vital Statistics System</article-title>. <source>NCHS Data Brief</source>. <year>2010</year>;(<issue>39</issue>):<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr39-0009922812456238">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>AH</given-names></name>
<name><surname>Reiter</surname><given-names>EO</given-names></name>
<name><surname>Geffner</surname><given-names>ME</given-names></name>
<etal/>
</person-group>. <article-title>Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1989</year>;<volume>69</volume>:<fpage>709</fpage>-<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr40-0009922812456238">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Temeck</surname><given-names>JW</given-names></name>
<name><surname>Pang</surname><given-names>SY</given-names></name>
<name><surname>Nelson</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Genetic defects of steroidogenesis in premature pubarche</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1987</year>;<volume>64</volume>:<fpage>609</fpage>-<lpage>617</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>